Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > UC Santa Barbara and Burnham Institute for Medical Research Announce Director of New Joint Research Center for Nanomedicine

Jamey D. Marth
Jamey D. Marth

Abstract:
UC Santa Barbara and Burnham Institute for Medical Research Announce Director of New Joint Research Center for Nanomedicine

UC Santa Barbara and Burnham Institute for Medical Research Announce Director of New Joint Research Center for Nanomedicine

Santa Barbara, CA | Posted on August 12th, 2009

The Burnham Institute for Medical Research and the University of California, Santa Barbara have named leading biomedical researcher Jamey D. Marth director of a new joint Center for Nanomedicine that will be established at UCSB.

The collaborative biomedical research partnership merges UCSB's core expertise in engineering, materials sciences, nanotechnology, and physics with Burnham's strengths in the biological sciences and biomedical research. The new center will promote the convergence of these fields and pioneer the development of novel technologies for advancing human health. Together, UCSB and Burnham plan to recruit additional scientists to the Center for Nanomedicine to create collaborative research teams that will produce innovative technologies for an entirely new generation of biosensors, medical devices, drug delivery nanoparticles, instruments for advanced biomedical research, and other products.

Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for curing disease or repairing damaged tissues, such as bone, muscle, or nerve.

"Interdisciplinary nanotechnologies are vital to establishing a holistic and rigorous approach to biomedical research that encompasses disparate knowledge and integrates all of the cellular molecules and factors that contribute to disease," said Marth, who joined UCSB's faculty in the Department of Molecular, Cellular, and Developmental Biology (MCDB), as well as Burnham's faculty, on July 1.

At UCSB, Marth has been appointed to two prestigious endowed professorships. He is the first recipient of both the John Carbon Chair in Biochemistry and Molecular Biology and the Duncan and Suzanne Mellichamp Chair in Systems Biology in the campus's Biomolecular Science and Engineering Program. Prior to joining Burnham and UCSB, Marth was professor of cellular and molecular medicine and Howard Hughes Medical Institute Investigator at the UC San Diego School of Medicine.

"With appointments to both UCSB and Burnham, I look forward to building further bridges between the talented scientists at these institutions and to promoting our joint efforts to develop nanotechnologies for disease diagnosis, prevention, therapy, and cure," said Marth. "This new and timely initiative will require the expertise of engineers, physicists, bioinformatics experts, and materials scientists working in close collaboration with biologists, that builds on the complementary expertise that exists at UCSB and the Burnham Institute for Medical Research."

Marth's laboratory is world-renowned in the application of cellular biology to uncovering the origins of disease. Marth is engaged in collaborative projects with UCSB and Burnham Institute scientists to develop nanotechnology platforms for biomedical research, including the means to rapidly detect and manipulate the cellular components that are responsible for health and disease. His highly interdisciplinary research has led to the discovery of disease mechanisms that span multiple fields, including autoimmune disease, infectious disease, and dietary-induced Type 2 diabetes.

"We are pleased to welcome an elite scientist like Dr. Marth to Burnham and to this collaborative partnership with UCSB in the exciting field of nanomedicine," said Dr. John Reed, Burnham's president and chief executive officer, and professor and Donald Bren Presidential Chair at the institute. "The impact of our collaborative efforts will be far-reaching, not only in terms of advancing the science of nanomedicine, but in terms of economic development opportunities for new company generation and job creation."

Pierre Wiltzius, Worster Dean of Science and professor of physics at UCSB, noted that Marth will play a central role in shaping the future of biomedical research on campus and described him as a "truly stellar biomolecular scientists who merits these prestigious endowed chairs."

"The coupling of biomolecules to nanomaterials and their assembly into nanostructures will produce a wide range of ‘smart' devices with an enormous breadth of practical applications, including diagnostics and biosensors, drug screening and delivery, tissue engineering, and much more," Wiltzius added. "The impact of this new field of science, termed ‘nanomedicine,' on medicine and life sciences will be hugely transformative, comparable in magnitude to the transition from transistors to silicon chips in the computer sciences."

Larry Coldren, acting dean of UCSB's College of Engineering and Kavli Professor of Optoelectronics and Sensors, described the new center's collaborative opportunities in nanomedicine and systems biology as a "perfect complement" to research underway at UCSB on networked systems approaches to drug development and therapies. "The combination of Jamey Marth's interests in disease mechanisms with our strengths in bioengineering and computational and materials sciences will be highly synergistic, and could well lead to major advances in therapies for grievous human diseases," he said.

Burnham established an affiliation with UCSB in 2006, led by internationally renowned biomedical researcher Erkki Ruoslahti, M.D., Ph.D. Dr. Ruoslahti maintained his primary appointment as Distinguished Professor with Burnham and joined UCSB's Department of Molecular, Cellular, and Developmental Biology as an adjunct Distinguished Professor. This type of collaboration, involving a highly ranked university and a nonprofit, independent research institute, exemplifies the inherent value of interdisciplinary research and the enhanced potential created when two such entities join forces.

"Professor Marth will invigorate interdisciplinary biomedical research at UC Santa Barbara, not only with his own exciting research in the Molecular, Cellular and Developmental Biology Department, but also with expansion of the Burnham Institute at UCSB," said Dennis O. Clegg, co-director of UCSB's Center for Stem Cell Biology and Engineering, and professor and recent past chair of MCDB. "Burnham is one the premier forces in medical research in the world, and expansion of the partnership with UCSB will enable novel approaches to uncover the molecular mechanisms of disease."

####

About University of California, Santa Barbara
About Engineering and the Sciences at UCSB

Engineering and the sciences at UC Santa Barbara are considered leaders in bioengineering, chemical and computational engineering, marine and environmental science, materials science, nanotechnology, and physics. UCSB has five Nobel laureates on its faculty.

About the Carbon Chair and the Mellichamp Chair

Endowed chairs are highly prized academic positions established with philanthropic gifts. They enable a university to recruit and retain outstanding faculty and to develop more fully a field of study by providing chair holders with ongoing financial support for enhanced research and instruction. The John Carbon Chair is named in honor of UCSB Emeritus Professor John Carbon, a pioneering biochemist who made numerous contributions to advance medical research. Carbon served as one of the original scientific advisors to Amgen. The chair was established by the Amgen Foundation, the William K. Bowes, Jr. Foundation, the Franklin and Catherine Johnson Foundation, and the Rathmann Family Foundation. The Mellichamp Chair was created by Emeritus UCSB Chemical Engineering Professor Duncan Mellichamp and his wife, Suzanne, to support research in the emerging field of systems biology.

About Burnham Institute for Medical Research

Burnham Institute for Medical Research is dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Burnham, with operations in California and Florida, is one of the fastest growing research institutes in the country. The institute ranks among the top four institutions nationally for NIH grant funding. For the past decade (1999-2009), Burnham has ranked number one worldwide in the fields of biology and biochemistry for the impact of its research publications (defined by citations per publication), according to the Institute for Scientific Information. Burnham utilizes a unique, collaborative approach to medical research and has established major research programs in cancer, neurodegeneration, diabetes, and infectious, inflammatory, and childhood diseases. The institute is especially known for its world-class capabilities in stem cell research and drug discovery technologies.

For more information, please click here

Contacts:
Eileen Conrad
805-893-8726

Josh Baxt
858-795-5236

Copyright © University of California, Santa Barbara

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease February 22nd, 2018

MEMS chips get metatlenses: Combining metasurface lenses with MEMS technology could add high-speed scanning and enhance focusing capability of optical systems February 21st, 2018

Atomic structure of ultrasound material not what anyone expected February 21st, 2018

Oxford Instruments announces Dr Kate Ross as winner of the 2018 Lee Osheroff Richardson Science Prize for North and South America February 20th, 2018

Nanomedicine

Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease February 22nd, 2018

Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B February 15th, 2018

Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT February 15th, 2018

'Living bandages': NUST MISIS scientists develop biocompatible anti-burn nanofibers February 15th, 2018

Sensors

Graphene on toast, anyone? Rice University scientists create patterned graphene onto food, paper, cloth, cardboard February 13th, 2018

Leti Chief Scientist Barbara De Salvo Will Help Kick Off ISSCC 2018 with Opening-Day Keynote: In Addition, Leti Scientists Will Present and Demo New Technology for Piezoelectric Energy Harvesting February 8th, 2018

Engineers develop flexible, water-repellent graphene circuits for washable electronics January 24th, 2018

Leti to Demo New Curving Technology at Photonics West that Improves Performance of Optical Components January 18th, 2018

Announcements

Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease February 22nd, 2018

MEMS chips get metatlenses: Combining metasurface lenses with MEMS technology could add high-speed scanning and enhance focusing capability of optical systems February 21st, 2018

Atomic structure of ultrasound material not what anyone expected February 21st, 2018

Oxford Instruments announces Dr Kate Ross as winner of the 2018 Lee Osheroff Richardson Science Prize for North and South America February 20th, 2018

Appointments/Promotions/New hires/Resignations/Deaths

Ocean Optics Grows Sales Organization with Executive Appointments: Henry Langston promoted, Christine Stannard joins spectral sensing product developer December 23rd, 2017

Emmanuel Sabonnadiere is Leti’s New CEO November 28th, 2017

Nanometrics Board of Directors Names Pierre-Yves Lesaicherre President and CEO November 14th, 2017

180 Degree Capital Corp. Appoints Investment Banking Veteran Parker Weil to Its Board of Directors August 2nd, 2017

Nanobiotechnology

Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease February 22nd, 2018

Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B February 15th, 2018

Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT February 15th, 2018

'Living bandages': NUST MISIS scientists develop biocompatible anti-burn nanofibers February 15th, 2018

Alliances/Trade associations/Partnerships/Distributorships

New era in high field superconducting magnets – opening new frontiers in science, nanotechnology and materials discovery January 9th, 2018

Leti Field Trials Demonstrate New Multicarrier Waveform for Rural, Maritime Broadband Radio: Field Trial in Orkney Islands Used New Filtered Multicarrier Waveform at 700MHz Band with Flexible Bandwidth Usage (Fragmented and Continuous Spectrum) December 18th, 2017

A new product to help combat mouldy walls, thanks to technology developed at the ICN2 December 14th, 2017

JPK Instruments announce partnership with Swiss company, Cytosurge AG. The partnership makes Cytosurge’s FluidFM® technology available on the JPK NanoWizard® AFM platform December 8th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project